| 1 |
25712735 | Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. | 2015 Jun |
2 |
| 2 |
25765803 | [Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib]. | 2015 Feb |
1 |
| 3 |
25814086 | The interferon-alpha revival in CML. | 2015 Apr |
3 |
| 4 |
23934954 | Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. | 2014 Feb 15 |
1 |
| 5 |
24553365 | Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. | 2014 Jun |
1 |
| 6 |
22684027 | Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia. | 2012 Jul |
1 |
| 7 |
20845478 | Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. | 2011 Jan 15 |
1 |
| 8 |
20922524 | Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation. | 2011 Apr |
1 |
| 9 |
21143150 | Interferon alpha for treatment of chronic myeloid leukemia. | 2011 Mar 1 |
3 |
| 10 |
21821707 | Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. | 2011 Oct 13 |
1 |
| 11 |
20142590 | Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. | 2010 Mar 10 |
3 |
| 12 |
19062090 | Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. | 2009 May |
1 |
| 13 |
17692911 | Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. | 2008 Feb |
1 |
| 14 |
17932248 | Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. | 2008 Feb 1 |
1 |
| 15 |
18679373 | Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. | 2008 Nov |
1 |
| 16 |
17607681 | Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. | 2007 Aug 15 |
3 |
| 17 |
17970609 | Targeted chronic myeloid leukemia therapy: seeking a cure. | 2007 Oct |
1 |
| 18 |
16533530 | Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. | 2006 Oct |
1 |
| 19 |
16630657 | Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. | 2006 Dec |
1 |
| 20 |
17106015 | Chronic myeloid leukemia: standard treatment options. | 2006 Dec 1 |
2 |
| 21 |
17263225 | [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up]. | 2006 Jun |
1 |
| 22 |
15671523 | U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. | 2005 Jan 1 |
2 |
| 23 |
15739029 | Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. | 2005 |
1 |
| 24 |
15794712 | The development and application of imatinib. | 2005 Mar |
1 |
| 25 |
16042686 | Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. | 2005 Aug |
2 |
| 26 |
14734453 | Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. | 2004 Jan 1 |
3 |
| 27 |
15128424 | Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. | 2004 Jun |
1 |
| 28 |
15161340 | Spotlight on imatinib mesylate in chronic myeloid leukemia. | 2004 |
1 |
| 29 |
15245690 | Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. | 2004 Jul |
1 |
| 30 |
12783377 | The cytogenetic response as a surrogate marker of survival. | 2003 Apr |
1 |
| 31 |
12857554 | Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. | 2003 Jul |
1 |
| 32 |
12970765 | Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. | 2003 Sep |
1 |
| 33 |
14508830 | Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. | 2003 Oct 1 |
1 |
| 34 |
14513038 | Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). | 2003 Oct |
1 |
| 35 |
14523462 | Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. | 2003 Dec |
1 |
| 36 |
14555307 | Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. | 2003 Oct |
4 |
| 37 |
14635203 | Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. | 2003 Dec |
2 |
| 38 |
14669283 | Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. | 2003 Dec 15 |
1 |
| 39 |
12114418 | Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. | 2002 Jul |
2 |
| 40 |
12374669 | Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. | 2002 Oct |
1 |
| 41 |
12389876 | Imatinib mesylate, the first molecularly targeted gene suppressor. | 2002 Oct |
2 |
| 42 |
11526598 | Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. | 2001 Jul |
2 |
| 43 |
10812245 | The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. | 2000 May |
1 |